Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

(2014) D. W. Bowles et al.   CLINICAL CANCER RESEARCH

Subconjunctival Palomid 529 in the treatment of neovascular age-related macular degeneration

(2013) Monica Dalal et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

(2013) Istvan Lang et al.   LANCET ONCOLOGY

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

(2012) Nicole Grabinski et al.   Molecular Cancer

Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates

(2011) M. Mazzoletti et al.   CANCER RESEARCH

Subconjunctival sirolimus in the treatment of diabetic macular edema

(2011) Nupura Krishnadev et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

(2011) Didier Roulin et al.   Molecular Cancer

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrating multiple genome annotation databases improves the interpretation of microarray gene expression data

(2010) Jun Yin et al.   BMC GENOMICS

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Complications of intravitreal injections

(2010) Kapil M Sampat et al.   CURRENT OPINION IN OPHTHALMOLOGY

Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In Vitro and In Vivo

(2010) Johannes Werzowa et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

(2009) F. I. Raynaud et al.   MOLECULAR CANCER THERAPEUTICS

Selective Inhibition of Retinal Angiogenesis by Targeting PI3 Kinase

(2009) Yolanda Alvarez et al.   PLoS One

Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)

(2008) M Georgopoulos et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration

(2008) Mariona Graupera et al.   NATURE

Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations

(2008) Brian G. Short   TOXICOLOGIC PATHOLOGY

Targeting phosphoinositide 3-kinase—Moving towards therapy

(2007) Romina Marone et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS